

Deep Spatial Phenotyping of Microglia in Human Alzheimer's Disease Brain Tissue


Aditya Pratapa¹, Paula Sanchez-Molina², Jasmine Singh¹, Aude Chiot², Alina Bogachuk², Nadezhda Nikulina¹, Randy Woltjer³, Bahareh Ajami², Oliver Braubach¹ ¹Akoya Biosciences, Marlborough, MA; ²Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, ³Department of Pathology, Oregon Health and Science University, Portland, OR

Poster 276.08

1. Introduction


Neuroinflammation is increasingly linked to the etiology and progression of Alzheimer's disease (AD). Microglia, the critical stewards of the brain's immune microenvironment, display phenotypic and state diversity in AD as shown in single-cell transcriptomic and proteomic analyses on tissue homogenates¹. These approaches lack spatial information, which is crucial to interpreting microglial involvement in neuroinflammation. We thus set out to develop a workflow that provides both, deep biomarker readouts and excellent spatial resolution. To this end, we developed a PhenoCycler®-Fusion (PCF) workflow that is compatible with formalin-fixed human brain tissue. The PCF is a novel spatial biology platform that generates ultrahigh-plex spatial data for millions of cells on a single tissue section within a matter of hours. Using this technology, we characterized the immune microenvironment – with emphasis on microglia – in normal and AD brain tissues. Our findings suggest an enrichment of certain microglial subtypes in AD brain tissues and in proximity to A β plaques. In its sum, this study provides (1) a method for ultrahigh-plex immunofluorescent analyses of AD pathology and new insights into the inflammatory microenvironment of AD.

2. PhenoCycler-Fusion Workflow










commercially



The **PhenoCycler-Fusion** workflow i

Antibodies can also be customized via

conjugation to activated oligonucleotide

existing antibody panels (e.g. Neuro Panel

antibodies are titrated and tested for

appropriate target recognition, and then

added to a panel. We routinely deploy

panels with >100 antibodies.

Following conjugation,


barcodes that are complementary

antibodies

TMEM119 Microglia Microglia & N-filament Macrophages Microglia & Oligodendrogl Macrophages Vimentin Proliferating ce Vascular Collagen IV Vascular Claudin-5 Vascula Macrophages

> Cytotoxic T cells APCs (MHC II) Immune cells Monocytes

Immune ABs



Vascular


Synaptic


H2A.X


Olig-2


PSD-95


Syp-physin Synaptic























The PhenoCycler-Fusion workflow consists of iterative cycles of labelling, imaging and removing fluorescent reporters. In each imaging cycle, three fluorescent reporters are assayed to their corresponding barcode-conjugated antibodies and imaged via standard fluorescent optics. Thereafter, the three reporters are removed, and a new cycle images additional reporters. The process is fully automated, and data are acquired across




distance from mature and immature plaques. (F) Mapping resident vs. systemic immune cells is key to understanding the AD inflammation. We have combined markers for the vasculature with immune cell antibodies to distinguish these systems.

3. Comprehensive Mapping of Alzheimer's Pathology in Human Brain Tissue


maturation levels. (C) Astroglia engage mainly mature A β plaques, i.e. those stained with A β

4. Stardist Nuclear Segmentation for Neuronal Cell Classification




and ApoE antibodies. (D-E) Microglia express AB 16A1 CD163

inflammatory biomarkers relative to their




(A) Fluorescent image showing major cell-type defining markers. (B) Spatial map showing cell classification results for 110,088 DAPI-based segmentation masks, obtained using Stardist. GM: Grey Matter, WM: White Matter (WM).



(C) Stardist-based masks showing localized nuclear signals for Neurons (NeuN) and Oligodendrocytes (Olig2). (D) Overall abundance of Stardistidentified cells is similar in GM (n= 59,783) and WM (n=50,305), with more oligodendrocytes in WM vs. more neurons in GM.


The Stardist cell masks failed to capture cellular processes in astrocytes and microglia (see GFP & IBA1 on left). To correctly segment individual microglia, we thus developed OTSM (pronounced 'Awesome'), which stands for Otsu's Thresholding based Segmentation and Merge. This method obtains a binary mask around microglial cells using Otsu's thresholding (2), followed by a merging step to merge disconnected processes using a predetermined distance cutoff. **Box 5** summarizes our results.

5. OTSM ('Awesome') Segmentation Accurately Registers Microglia



(A) Image showing microglia and Aβ plaque staining. (B) DAPI-based Stardist nuclear masks; arrows show processes of one cell that extend into the Stardist mask of an adjacent one. (C) OTSM Microglial cell masks and (D) OTSM predicted Aβ plaque mask. (E) Combined masks used for subsequent analysis. (F) tSNE plots showing 11 microglial clusters obtained using unsupervised Leiden clustering of 48,146 cells. Clusters are colored by cluster number (left), specimen (middle) and sample type (right). (G) Heatmap showing mean expression of 10 microglial markers used for clustering. **OTSM** enabled phenotyping of microglia based on markers expressed in their ramifications.

6. Inflammatory State of Microglia Depends on Proximity to Aß Plaques



7. Conclusions and Outlook

- More than five million Americans are living with Alzheimer's Disease, but our understanding of the etiology and progression of this disease remains limited.
- We developed a comprehensive Spatial Biology workflow aimed at uncovering the inflammatory biology of AD in human patient samples in situ.
- Our work encompasses the development of a custom antibody panel, an imaging workflow, as well as a novel bioinformatic analysis method.
- Deployment of this workflow on post-mortem AD tissues allowed us to study different microglial cell populations, according to biomarker profiles and spatial distribution; in doing so, we identified different area and disease-associated microglial subpopulations in the cerebral cortex.
- Our workflow will allow large-scale unsupervised analyses of the AD inflammatory microenvironment that is needed to better characterize neurodegenerative disease.
- I. Wang H (2021). Microglia Heterogeneity in Alzheimer's Disease: Insights From Single-Cell Technologies
- 2. N. Otsu (1979). A Threshold Selection Method from Gray-Level Histograms, IEEE Trans. on Sys, Man, &

This study was supported by Alzheimer's Association Grant #AARGD-22-928829 to BA.

whole slides at single-cell resolution.